Results 151 to 160 of about 51,995 (213)

Authors' Reply: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study. [PDF]

Epidemiol Health
Lee H, Hong B, Tzu-Ting Su C, Bea S, Jeong HE, Jung K, Cheng MC, Chang ZC, Lai EC, Lee J.   +9 more
europepmc   +1 more source

Book Review: Global Health and Global Aging [PDF]

, 2009
Abouzaid, Safiya, PharmD
core   +1 more source

Pharmacoequity in Anticoagulation Among Medicare Patients With Venous Thromboembolism.

JAMA Netw Open
Alkhalaf AA, Bea S, Iyer GS, Lauffenburger JC, Bykov K.   +4 more
europepmc   +1 more source

Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations. [PDF]

Pharmacoeconomics
Meier N, Quiroga Gutierrez AC, Pletscher M, Schwenkglenks M.   +3 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain. [PDF]

Pharmacoecon Open
Romero Jiménez RM, Herranz Pinto P, Campos Domínguez M, Bellmunt A, Vidal-Vilar N, Fortes Soto MDP, De Lossada Juste A.   +6 more
europepmc   +1 more source

Practical Considerations for Incorporating Equity More Explicitly in Australian Health Technology Assessment Processes. [PDF]

Pharmacoeconomics
Killedar A, Howell M, Howard K, Norris S.   +3 more
europepmc   +1 more source

Value of Clinical Evidence and Health Economics and Outcomes Research (HEOR) Studies. [PDF]

Muscle Nerve
Abrahao A, Ciepielewska M, Zinman L.
europepmc   +1 more source

How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study. [PDF]

Glob Health Res Policy
Cheng H, Jiang S, Liu T, Li B, Chen S, Li A, Chen H, Wang H, Gu Y.   +8 more
europepmc   +1 more source